Skip to main content
Clinical Trials/JPRN-UMIN000012817
JPRN-UMIN000012817
Recruiting
Phase 2

Randomized controlled trial for peripheral neuropathy comparing weekly Paclitaxel followed by FEC100 with Eribulin Mesilate followed by FEC100 as neoadjuvant chemotherapy in primary breast cancer patients. - JONIE 3 Study

JONIE Study Group0 sites230 target enrollmentJanuary 11, 2014

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Operable early Breast Cancer
Sponsor
JONIE Study Group
Enrollment
230
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 11, 2014
End Date
December 31, 2020
Last Updated
2 years ago
Study Type
Interventional
Sex
Female

Investigators

Sponsor
JONIE Study Group

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • (1\)Non\-invasive breast cancer and Invasive micropapillary carcinoma (2\)Inflammatory breast caner (3\) Bilateral breast cancer(synchronous or asynchrous) (4\) No prior chemotherapy, endocrine therapy and radiotherapy for breast cancer (5\) Active double cancer (6\) Patients with myocardial infarction or congestive heart failure at the past history, or patients who need treatment of ischemic hear disease, arryhythmia or valvular disorder. (7\) Severe complication (infectious diseases, interstitial pneumonia peripheral neuropathy, uncontrolled diabetes, bleeding tendency) (8\) Those who are pregnant, potentially pregnant or breast\-feeding (9\) Those known to have active Hepatitis B or C Viral Infection (HBs(\+) or HCV(\+)) (10\)Patients who have an allergy for alcohol (11\) Patient judged inappropriate for this study by the physicians

Outcomes

Primary Outcomes

Not specified

Similar Trials